Journal of Clinical Medicine (Sep 2022)

Clinical Efficacy of Catheter Ablation in the Treatment of Vasovagal Syncope

  • Lingping Xu,
  • Yixin Zhao,
  • Yichao Duan,
  • Rui Wang,
  • Junlong Hou,
  • Jing Wang,
  • Bin Chen,
  • Ye Yang,
  • Xianjun Xue,
  • Yongyong Zhao,
  • Bo Zhang,
  • Chaofeng Sun,
  • Fengwei Guo

DOI
https://doi.org/10.3390/jcm11185371
Journal volume & issue
Vol. 11, no. 18
p. 5371

Abstract

Read online

Catheter ablation of ganglionated plexi (GPs) performed as cardioneuroablation in the left atrium (LA) has been reported previously as a treatment for vasovagal syncope (VVS). However, the efficacy and safety of catheter ablation in the treatment of VVS remains unclear. The objective of this study is to explore the efficacy and safety of catheter ablation in the treatment of VVS and to compare the different ganglion-mapping methods for prognostic effects. A total of 108 patients with refractory VVS who underwent catheter ablation were retrospectively enrolled. Patients preferred to use high-frequency stimulation (HFS) (n = 66), and anatomic landmark (n = 42) targeting is used when HFS failed to induce a positive reaction. The efficacy of the treatment is evaluated by comparing the location and probability of the intraoperative vagal reflex, the remission rate of postoperative syncope symptoms, and the rate of negative head-up tilt (HUT) results. Adverse events are analyzed, and safety is evaluated. After follow-up for 8 (5, 15) months, both HFS mapping and anatomical ablation can effectively improve the syncope symptoms in VVS patients, and 83.7% of patients no longer experienced syncope (<0.001). Both approaches to catheter ablation in the treatment of VVS effectively inhibit the recurrence of VVS; they are safe and effective. Therefore, catheter ablation can be used as a treatment option for patients with symptomatic VVS.

Keywords